Vireo Growth Inc.
Vireo Growth is a U.S.-based, vertically integrated cannabis company serving patients and adult-use customers through licensed subsidiaries. It cultivates cannabis in outdoor, indoor and greenhouse facilities, manufactures cannabis products, and sells them through its own dispensaries and to third-party businesses where permitted. Its products include flower, concentrates, vaporizer pens and cartridges, edibles, tablets, capsules, oral solutions, tinctures and topicals. Retail brands include Green Goods and Deep Roots Harvest. Vireo operates in Maryland, Minnesota, Missouri, Nevada, New York and Utah. As of March 17, 2026, it retails cannabis products in 36 dispensaries and wholesales products through third-party companies in those six states. Its corporate office is in Minneapolis, Minnesota.
No SEC Form 4 filings for $VREOF in the last 30 days.
See all $VREOF insider activity →Vireo Growth Inc. reported Q3 2026 revenue of $253.7M, up 177% YoY, driven by acquisitions. Proforma revenue was $277M. The company closed Q3 with $106.8M in cash and expects to remain acquisitive. Key acquisitions include C21 Investments and PharmaCann Colorado assets. Vireo launched a share repurchase program and expanded financing capacity.
Vireo Growth secured a $60 million 8.50% term loan from Needham Bank to refinance existing debt and acquire a Florida property. The loan matures in 2034 with a 6-month interest-only period. The company also repaid a $49 million Seller Note held by IIP-NY 2 without penalty, consolidating senior liens with Needham Bank.
Vireo Growth Inc. (VREOF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Vireo Growth Inc. Announces Financing for New York and Florida Cultivation Facility Transaction supports ownership of key cultivation and production infrastructure in Two Core Markets MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning VREOF (Vireo Growth Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent VREOF coverage spans corporate actions, earnings and mergers & acquisitions.
Strong top‑line growth and expanding footprint suggest upside potential, but margin compression and high debt may temper enthusiasm.
Vireo Growth obtained a $60M secured term loan at 8.5% to refinance existing debt and fund a property purchase.
The new credit facility provides low‑cost capital, likely supporting expansion and could reduce financing risk, which may be viewed positively by investors.
The deal expands Vireo's Nevada footprint, adding three dispensaries and 104k sq ft of cultivation capacity.
The filing confirms the asset deal is completed, which can change revenue mix, cash needs, and balance-sheet risk.
AlphAI scores every news story that mentions VREOF with an AI model for sentiment and relevance, and aggregates insider trades from Vireo Growth Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vireo Growth Inc. reported Q3 2026 revenue of $253.7M, up 177% YoY, driven by acquisitions. Proforma revenue was $277M. The company closed Q3 with $106.8M in cash and expects to remain acquisitive. Key acquisitions include C21 Investments and PharmaCann Colorado assets. Vireo launched a share repurchase program and expanded financing capacity.
Vireo Growth secured a $60 million 8.50% term loan from Needham Bank to refinance existing debt and acquire a Florida property. The loan matures in 2034 with a 6-month interest-only period. The company also repaid a $49 million Seller Note held by IIP-NY 2 without penalty, consolidating senior liens with Needham Bank.
Vireo Growth Inc. (VREOF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Vireo Growth Inc. Announces Financing for New York and Florida Cultivation Facility Transaction supports ownership of key cultivation and production infrastructure in Two Core Markets MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX
Vireo Growth Inc. (VREOF) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vireo Growth Inc. Completes Acquisition of C21 Investments Inc. 08/21/2026 Transaction expands Vireo’s Nevada footprint with three leading dispensaries in Nevada and approximately 104,000 sq. ft. of cultivation and production capacity MINNEAPOLIS and VANCOUVER, Briti
Vireo Growth Inc. (VREOF) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vireo Growth Announces Asset Based Credit Facility Facility enhances financial flexibility and supports continued execution of the Company's disciplined growth strategy MINNEAPOLIS, Minnesota, August 7, 2026 -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or
Vireo Growth Inc. (VREOF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vireo Growth Inc. Announces Second Quarter 2026 Results Q2 GAAP revenue of $209.3 million increased 335% year-over-year, driven by recently closed M&A transactions. Q2 proforma revenue of $254.9 million, gives effect to the acquisitions of Hawthorne, Bridgewell, and
Vireo Growth Inc. (VREOF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Vireo Growth Inc. Announces a Four-Deal Transaction to Establish Presence in Ohio 07/31/2026 Further Expands Vireo’s National Platform, Creating One of the Industry’s Broadest State Footprints MINNEAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VRE
Vireo Growth Inc. (VREOF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Merger Agreement On July 26, 2026, Vireo Growth Inc., a British Columbia corporation (“ Vireo ” or “ Parent ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Planet 13 Holdings Inc. , a Nevada co
Vireo Growth Inc. (VREOF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 tm2621146d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version Confidential PURCHASE AGREEMENT by and among VIREO HEALTH OF ARCADIA, LLC, COLUMBIA CARE LLC, THE CANNABIST COMPANY HOLDINGS INC., THE TRANSFERRED ENTITIES SET FORTH ON SCHEDULE A and THE SELLER ENTITIES
Motley Fool compares Trulieve Cannabis (NYSE: TRLV) and Vireo Growth (OTC: VREOF). Trulieve deconsolidated adult-use dispensaries into Harvest to qualify for NYSE listing, reporting Q1 revenue of $287M (-4% YoY) and EPS $0.02. Vireo reported Q1 revenue $106.2M (+333.5% YoY) and EPS loss $0.02, after acquisitions including Schwazze, Eaze, and Hawthorne.
